Other Events. As previously disclosed, on October 25, 2026, the Company’s board of directors (the “Board”) declared a special cash distribution to its stockholders in connection with the Merger (the “Cash Distribution”). The Company has determined that the aggregate amount of the Cash Distribution is $83.6 million, or $13.90 per share. The Cash Distribution will be payable in cash to stockholders and pre-funded warrant holders of record as of November 5, 2026 (the “Cash Distribution Record Da…

The filing describes the approval of a new equity incentive plan, which is a compensation arrangement rather than a change in management personnel.

Other Events. As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delaware corporation (“Avenzo”), and Farmington Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of the Company (“Merger Sub”), pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set…

CFO — Jonathan Lieber: The CFO is transitioning to part-time status but explicitly remains in the role with the same duties and authority, so this is a change in employment terms rather than a departure.

Changes in Control of Registrant. To the extent required by this Item, the information included in

The filing appears to be a placeholder or incomplete, without specific details about any management change.

Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in

Entry into a Material Definitive Agreement. Merger Agreement On May 31, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Avenzo Therapeutics, Inc., a Delaware corporation (“ Avenzo ”), a clinical-stage biotechnology company developing next-generation oncology therapies, and Farmington Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Rallybio (“ Merger Sub ”)…

Termination of a Material Definitive Agreement. As previously disclosed, on March 1, 2026, Rallybio Corporation (“ Rallybio ”) entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Candid Therapeutics, Inc. (“ Candid ”), and Farmington Merger Sub, Inc., a wholly-owned subsidiary of Rallybio (“ Merger Sub ”). For a description of the Merger Agreement, please refer to

of Rallybio’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “ SEC ”) on March 2, 2026 (the “ March 2026 8-K ”), which description is incorporated herein by reference. Such description is qualified in its entirety by reference to the full text of the Merger Agreement, which is attached as Exhibit 2.1 to the March 2026 8-K, which is incorporated herein by reference. On May 3, 2026, Candid terminated the Merger Agreement concurrently with entering into a Permi…

Chief Medical Officer — Steven Ryder, M.D.: Dr. Steven Ryder left Rallybio Corporation immediately.

Entry into a Material Definitive Agreement. Merger Agreement On March 1, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Candid Therapeutics, Inc., a Delaware corporation (“ Candid ”), a clinical-stage biotechnology company advancing a leading portfolio of T-cell engager (TCE) therapeutics for autoimmune diseases, and Farmington Merger Sub, Inc., a Delaware corporation and wholly…

The filing appears to be a placeholder or incomplete, without specific details about any management change.

Unregistered Sales of Equity Securities. To the extent required by this Item, the information included in

Changes in Control of Registrant. To the extent required by this Item, the information included in

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed by Rallybio Corporation (“the Company”), on February 24, 2025, the Company received a notification letter from The Nasdaq Stock Market LLC (“Nasdaq”) Listing Qualifications Department notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the prior 30 consecutive business…

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Completion of Acquisition or Disposition of Assets. The information set forth in

Entry into a Material Definitive Agreement. On July 8, 2025, Rallybio Corporation (“Rallybio”) entered into a Membership Interest Purchase Agreement (the “Purchase Agreement”) with Recursion Pharmaceuticals, Inc., (“Recursion”), Exscientia Ventures I, Inc., an indirect wholly-owned subsidiary of Recursion (“Buyer”) and Rallybio IPB, LLC, a wholly-owned subsidiary of Rallybio (“Seller”), pursuant to which Buyer purchased 50% of the issued and outstanding membership interests (the “Membership I…

Chief Medical Officer — Steven Ryder, M.D.: Dr. Steven Ryder entered into a new employment agreement with Rallybio Corporation as Chief Medical Officer.

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Other Events. On March 13, 2025, Rallybio Corporation (the “Company”) and TD Securities (USA) LLC (“TD Cowen”) entered into Amendment No. 1 (the “Amendment”) to the Sales Agreement dated August 8, 2022 (as amended, the “Sales Agreement”), which Amendment reduced the amount of the Company’s common stock, par value $0.0001 per share (the “Shares”), that can be sold by the Company under the Sales Agreement, from an aggregate offering price of up to $100,000,000 to an aggregate offering price of…

of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 24, 2025, Rallybio Corporation (the “Company” or “Rallybio”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price of the Company’s shares of common stock was below the minimum closing bid price of $1.00 per share during the last 30 consecutive business days (the “N…